JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

Search

Ascendis Pharma A-S ADR

Cerrado

SectorSalud

222.88 0.68

Resumen

Variación precio

24h

Actual

Mínimo

212.2

Máximo

224.32

Métricas clave

By Trading Economics

Ingresos

-22M

-61M

Ventas

56M

214M

Margen de beneficio

-28.549

Empleados

1,017

EBITDA

-56M

-53M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+24.73% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.8B

14B

Apertura anterior

222.2

Cierre anterior

222.88

Noticias sobre sentimiento de mercado

By Acuity

54%

46%

276 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 feb 2026, 17:25 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9 feb 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9 feb 2026, 23:43 UTC

Charlas de Mercado

Gold Falls on Possible Technical Correction -- Market Talk

9 feb 2026, 23:14 UTC

Charlas de Mercado

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9 feb 2026, 22:29 UTC

Charlas de Mercado

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9 feb 2026, 22:19 UTC

Charlas de Mercado

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9 feb 2026, 22:08 UTC

Charlas de Mercado

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9 feb 2026, 22:01 UTC

Ganancias

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9 feb 2026, 21:59 UTC

Ganancias

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9 feb 2026, 21:59 UTC

Ganancias

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9 feb 2026, 21:58 UTC

Ganancias

Friedman Industries 3Q Sales $168M >FRD

9 feb 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

9 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 feb 2026, 21:48 UTC

Ganancias

Friedman Industries 3Q EPS 43c >FRD

9 feb 2026, 21:17 UTC

Ganancias

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9 feb 2026, 21:13 UTC

Charlas de Mercado

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9 feb 2026, 21:04 UTC

Ganancias

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9 feb 2026, 20:30 UTC

Charlas de Mercado

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9 feb 2026, 20:02 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9 feb 2026, 19:42 UTC

Charlas de Mercado

Japan's Yield Curve Expected to Flatten -- Market Talk

9 feb 2026, 19:31 UTC

Charlas de Mercado

Nike Seen Regaining Relevance With Consumers -- Market Talk

9 feb 2026, 19:27 UTC

Charlas de Mercado

Gold Climbs Back Over $5,000/oz -- Market Talk

9 feb 2026, 19:05 UTC

Charlas de Mercado

Nike Returns to List of Hottest Brands -- Market Talk

9 feb 2026, 18:19 UTC

Charlas de Mercado

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9 feb 2026, 17:41 UTC

Ganancias
Adquisiciones, fusiones, absorciones

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9 feb 2026, 17:31 UTC

Ganancias
Adquisiciones, fusiones, absorciones

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9 feb 2026, 17:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

9 feb 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 feb 2026, 17:17 UTC

Charlas de Mercado

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9 feb 2026, 17:16 UTC

Ganancias

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

24.73% repunte

Estimación a 12 meses

Media 277.08 USD  24.73%

Máximo 342 USD

Mínimo 240 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

13

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

276 / 352 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat